Dendritic cells and cytokines in immune rejection of cancer

Cytokine and Growth Factor Reviews

Volumn 19, Issue 1, 2008, Pages 93-107

  Ferrantini, Maria ^a   Capone, Imerio ^a   Belardelli, Filippo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer immunity; Cytokines; Dendritic cells; Immune potentiators; Immunotherapy

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; CPG 7909; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DACARBAZINE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTERLEUKIN 12; MELAN A; MONTANIDE ISA 51; NY ESO 1 ANTIGEN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ACTINIC KERATOSIS; ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; CELL INTERACTION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONDYLOMA ACUMINATUM; DENDRITIC CELL; DRUG BINDING; DRUG MEGADOSE; HAIRY CELL LEUKEMIA; HEAD AND NECK CARCINOMA; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; MELANOMA; MONOTHERAPY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INTERACTION; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; CPG ISLANDS; CYTOKINES; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9;

EID: 38849173039     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2007.10.003     Document Type: Article

References (145)

1. Ehrlich P. Uber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 5 (1909) 273-290
2. Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J (1957) 779-786
3. Thomas L. Reactions to homologous tissue antigens in relation to hypersensitivity. In: Lawrence H.S. (Ed). Cellular and humoral aspects of the hypersensitive states (1959), Hoeber-Harper, New York 529-532
4. Novellino L., Castelli C., and Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54 (2005) 187-207
5. Jager E., Chen Y.T., Drijfhout J.W., Karbach J., Ringhoffer M., Jager D., et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187 (1998) 265-270
6. Yu P., and Fu Y.X. Tumor-infiltrating T lymphocytes: friends or foes?. Lab Invest 86 (2006) 231-245
7. Steinman R.M., and Banchereau J. Taking dendritic cells into medicine. Nature 449 (2007) 419-426
8. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
9. Hart D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90 (1997) 3245-3287
10. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 5 (1999) 919-923
11. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., et al. The nature of the principal type I interferon-producing cells in human blood. Science 284 (1999) 1835-1837
12. Shortman K., and Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2 (2002) 151-161
13. Shurin M.R., Shurin G.V., Lokshin A., Yurkovetsky Z.R., Gutkin D.W., Chatta G., et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?. Cancer Metastasis Rev 25 (2006) 333-356
14. Matzinger P. The danger model: a renewed sense of self. Science 296 (2002) 301-305
15. O'Hagan D.T., and Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2 (2003) 727-735
16. Hargreaves D.C., and Medzhitov R. Innate sensors of microbial infection. J Clin Immunol 25 (2005) 503-510
17. Creagh E.M., and O'Neill L.A. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 27 (2006) 352-357
18. Liu Y.J. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23 (2005) 275-306
19. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol Rev 199 (2004) 227-250
20. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., and Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6 (2005) 769-776
21. Tough D.F. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk Lymphoma 45 (2004) 257-264
22. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
23. Krieg A.M. Development of TLR9 agonists for cancer therapy. J Clin Invest 117 (2007) 1184-1194
24. Chaperot L., Blum A., Manches O., Lui G., Angel J., Molens J.P., et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 176 (2006) 248-255
25. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5 (2006) 471-484
26. Della Chiesa M., Romagnani C., Thiel A., Moretta L., and Moretta A. Multidirectional interactions are bridging human NK cells with plasmacytoid and monocyte-derived dendritic cells during innate immune responses. Blood 108 (2006) 3851-3858
27. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 (2004) 987-995
28. Schlecht G., Garcia S., Escriou N., Freitas A.A., Leclerc C., and Dadaglio G. Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. Blood 104 (2004) 1808-1815
29. Krug A., Veeraswamy R., Pekosz A., Kanagawa O., Unanue E.R., Colonna M., et al. Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J Exp Med 197 (2003) 899-906
30. Rothenfusser S., Hornung V., Ayyoub M., Britsch S., Towarowski A., Krug A., et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood 103 (2004) 2162-2169
31. Chagnon F., Tanguay S., Ozdal O.L., Guan M., Ozen Z.Z., Ripeau J.S., et al. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin Cancer Res 11 (2005) 1302-1311
32. Pasare C., and Medzhitov R. Toll pathway-dependent blockade of CD4+ CD25+ T cell-mediated suppression by dendritic cells. Science 299 (2003) 1033-1036
33. Kubo T., Hatton R.D., Oliver J., Liu X., Elson C.O., and Weaver C.T. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells. J Immunol 173 (2004) 7249-7258
34. Sutmuller R.P., den Brok M.H., Kramer M., Bennink E.J., Toonen L.W., Kullberg B.J., et al. Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest 116 (2006) 485-494
35. Moseman E.A., Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., Liu Y.J., et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+ CD25+ regulatory T cells. J Immunol 173 (2004) 4433-4442
36. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., and Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 (2006) 179-189
37. McCluskie M.J., and Krieg A.M. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. In: Pulendran B., and Ahmed R. (Eds). From innate immunity to immunological memory (2006), Springer, New York, USA 155-178
38. Suzuki Y., Wakita D., Chamoto K., Narita Y., Tsuji T., Takeshima T., et al. Liposome-Encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res 64 (2004) 8754-8760
39. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8(+) T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115 (2005) 739-746
40. Appay V., Jandus C., Voelter V., Reynard S., Coupland S.E., Rimoldi D., et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 177 (2006) 1670-1678
41. Valmori D., Souleimanian N.E., Tosello V., Bhardwaj N., Adams S., O'Neill D., et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104 (2007) 8947-8952
42. Molenkamp B.G., van Leeuwen P.A.M., Meijer S., Sluijter B.J.R., Wijnands PGJTB, Baars A., et al. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 13 (2007) 2961-2969
43. Berraondo P., Nouze C., Préville X., Ladant D., and Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 67 (2007) 8847-8855
44. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3 (2002) 196-200
45. Gaspari A.A. Mechanism of action and other potential roles of an immune response modifier. Cutis 79 (2007) 36-45
46. Urosevic M., Maier T., Benninghoff B., Slade H., Burg G., and Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 139 (2003) 1325-1332
47. Stockfleth E., Trefzer U., Garcia-Bartels C., Wegner T., Schmook T., and Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 149 (2003) 53-56
48. Stanley M.A. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27 (2002) 571-577
49. Hurwitz D.J., Pincus L., and Kupper T.S. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol 139 (2003) 1347-1350
50. Urosevic M., Dummer R., Conrad C., Beyeler M., Laine E., Burg G., et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 97 (2005) 1143-1153
51. Sullivan T.P., Dearaujo T., Vincek V., and Berman B. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg 29 (2003) 1181-1186
52. Peng G., Guo Z., Kiniwa Y., Voo K.S., Peng W., Fu T., et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 309 (2005) 1380-1384
53. Schön M.P., Schön M., and Klotz K.N. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol 126 (2006) 1338-1347
54. Schön M., Bong A.B., Drewniok C., Herz J., Geilen C.C., Reifenberger J., et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95 (2003) 1138-1149
55. Grebenova D., Kuzelova K., Fuchs O., Halada P., Havlicek V., Marinov I., et al. Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis. Blood Cells Mol Dis 32 (2004) 262-269
56. Majewski S., Marczak M., Mlynarczyk B., Benninghoff B., and Jablonska S. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis. Int J Dermatol 44 (2005) 14-19
57. Li V.W., Li W.W., Talcott K.E., and Zhai A.W. Imiquimod as an antiangiogenic agent. J Drugs Dermatol 4 (2005) 708-717
58. Smith K.J., Hamza S., and Skelton H. Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern. Clin Exp Dermatol 29 (2004) 505-512
59. Michalopoulos P., Yawalkar N., Brönnimann M., Kappeler A., and Braathen L.R. Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol 151 (2004) 903-906
60. Barnetson R.S., Satchell A., Zhuang L., Slade H.B., and Halliday G.M. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma (BCC) is associated with early infiltration by CD4 T cells and dendritic cells. Clin Exp Dermatol 29 (2004) 639-643
61. Wolf I.H., Kodama K., Cerroni L., and Kerl H. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol 29 (2007) 237-241
62. KEGG PATHWAY Database [http://www.genome.ad.jp/kegg/pathway.html].
63. Panelli M.C., Stashower M.E., Slade H.B., Smith K., Norwood C., Abati A., et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 8 (2007) R8
64. Stary G., Bangert C., Tauber M., Strohal R., Kopp T., and Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 204 (2007) 1441-1451
65. Xu W., Liu L., and Charles I.G. Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J 16 (2002) 213-215
66. Mocellin S., Provenzano M., Lise M., Nitti D., and Rossi C.R. Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma. Int J Cancer 107 (2003) 317-322
67. Craft N., Bruhn K.W., Nguyen B.D., Prins R., Wei Lin J., Liau L.M., et al. The TLR7 agonist Imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine. J Immunol 175 (2005) 1983-1990
68. Prins R.M., Craft N., Bruhn K.W., Khan-Farooqi H., Koya R.C., Stripecke R., et al. The TLR-7 agonist, Imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176 (2006) 157-163
69. Nair S., McLaughlin C., Weizer A., Su Z., Boczkowski D., Dannull J., et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171 (2003) 6275-6282
70. Shackleton M., Davis I.D., Hopkins W., Jackson H., Dimopoulos N., Tai T., et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 4 (2004) 9
71. Belardelli F., and Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23 (2002) 201-208
72. Santini S.M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-scid mice. J Exp Med 191 (2000) 1777-1788
73. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6 (2006) 595-601
74. Feili-Hariri M., Falkner D.H., and Morel P.A. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy. J Leukoc Biol 78 (2005) 656-664
75. Tourkova I.L., Shurin G.V., Chatta G.S., Perez L., Finke J., Whiteside T.L., et al. Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J Immunol 175 (2005) 3045-3052
76. + T cells to differentiate into CTL. Eur J Immunol 37 (2007) 1678-1690
77. Del Vecchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 13 (2007) 4677-4685
78. Curtsinger J.M., Lins D.C., and Mescher M.F. Signal 3 determines tolerance versus full activation of naïve CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 197 (2003) 1141-1151
79. Kalinski P., Hilkens C.M., Wierenga E.A., and Kapsenberg M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20 (1999) 561-567
80. + T cells through phosphatidylinositol 3-kinase/Akt signaling pathway. J Immunol 169 (2002) 3637-3643
81. + T cell responses in vitro. J Immunother 30 (2007) 75-82
82. Colombo M.P., and Trinchieri G. Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev 13 (2002) 155-168
83. Chang D.Z., Lomazow W., Joy Somberg C., Stan R., and Perales M.A. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 9 (2004) 207-215
84. Mach N., Gillessen S., Wilson S.B., Sheehan C., Mihm M., and Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 60 (2000) 3239-3246
85. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M.P., and Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18 (2007) 226-232
86. Serafini P., De Santo C., Marigo I., Cingarlini S., Dolcetti L., Gallina G., et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53 (2004) 64-82
87. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., and Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64 (2004) 6337-6343
88. Serafini P., Borrello I., and Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16 (2006) 53-65
89. Young M.R.I., Wright M.A., and Pandit R. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. J Immunol 159 (1997) 990-996
90. Garrity T., Pandit R., Wright M.A., Benefield J., Keni S., and Young M.R. Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int J Cancer 73 (1997) 663-669
91. Rössner S., Voigtländer C., Wiethe C., Hänig J., Seifarth C., and Lutz M.B. l. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol 35 (2005) 3533-3544
92. Gabrilovich D. Mechanisms and functional significance of tumor-induced dendritic-cell defects. Nat Rev Immunol 4 (2004) 941-952
93. Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity 25 (2006) 343-348
94. Gutterman J.U. Cytokine therapeutics: lessons from interferon-alpha. Proc Natl Acad Sci USA 91 (1994) 1198-1205
95. Gresser I. The antitumor effects of interferon: a personal history. Biochimie 89 (2007) 723-728
96. Belardelli F., Ferrantini M., Proietti E., and Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13 (2002) 119-134
97. Dunn G.P., Koebel C.M., and Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6 (2006) 836-848
98. Wu J.C., Yang X.F., McLaughlin S., Neuberg D., Canning C., Stein B., et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukaemia. J Clin Invest 106 (2000) 705-714
99. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6 (2000) 1018-1023
100. Gogas H., Ioannovich J., Dafni U., Stavropoulou-Giokas C., Frangia K., Tsoutsos D., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354 (2006) 709-718
101. Ferrantini M., Capone I., and Belardelli F. Interferon-α and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89 (2007) 884-893
102. Tough D.F., Borrow P., and Sprent J. Induction of bystander T-cell proliferation by viruses and type I interferon in vivo. Science 272 (1996) 1947-1950
103. Sun S., Zhang X., Tough D.F., and Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 188 (1998) 2335-2342
104. Paquette R.L., Hsu N.C., Kiertscher S.M., Park A.N., Tran L., Roth M.D., et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukocyte Biol 64 (1998) 358-367
105. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N., Trapani J., et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161 (1998) 1947-1953
106. Radvanyi L.G., Banerjee A., Weir M., and Messner H. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand. J Immunol 50 (1999) 499-500
107. + T-cell response. J Immunol 170 (2003) 5195-5202
108. Lapenta C., Santini S.M., Logozzi M., Spada M., Andreotti M., Di Pucchio T., et al. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated-virus-pulsed dendritic cells generated in the presence of IFN-α. J Exp Med 198 (2003) 361-367
109. + T-cell responses against human tumor antigens. J Immunol 172 (2004) 5363-5370
110. + T-cell help. Eur J Immunol 36 (2006) 2046-2060
111. Banchereau J., and Pascual V. Type I IFN in systemic lupus erythematosus and other autoimmune diseases. Immunity 25 (2006) 383-392
112. Wang C., Al-Omar H.M., Radvanyi L., Banerjee A., Bouman D., Squire J., et al. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-α. Exp Hematol 27 (1999) 1176-1184
113. Chen X., Regn S., Raffegerst S., Kolb H.J., and Roskrow M. Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. Br J Haematol 111 (2000) 596-607
114. Gabriele L., Borghi P., Rozera C., Sestili P., Andreotti M., Guarini A., et al. IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 103 (2004) 980-987
115. Cortes J., Kantarjian H.M., O'Brien S., Kurzrock R., and Talpaz M. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukaemia. Leukemia 12 (1998) 860-864
116. Koon H., and Atkins M. Autoimmunity and immunotherapy of cancer. N Engl J Med 354 (2006) 758-760
117. + T cells and monocyte/dendritic cell precursors. Cancer Res 66 (2006) 4943-4951
118. Astsaturov I., Petrella T., Bagriacik U., de Benedette M., Uger R., Lumber G., et al. Amplification of virus-induced antimelanoma T-cell reactivity by high dose interferon-α-2b: implications for cancer vaccines. Clin Cancer Res 9 (2003) 4347-4355
119. Hoeffel G., Ripoche A.C., Matheoud D., Nascimbeni M., Escriou N., Lebon P., et al. Antigen cross presentation by human plasmacytoid dendritic cells. Immunity 27 (2007) 481-492
120. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449 (2007) 564-569
121. Baccala R., Hoebe K., Kono D.H., Beutler B., and Theofilopoulos A.N. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 13 (2007) 543-551
122. Langenkamp A., Messi M., Lanzavecchia A., and Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1 (2000) 311-316
123. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
124. Nestle F.O., Farkas A., and Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 17 (2005) 163-169
125. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5 (2005) 296-306
126. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61 (2001) 6451-6458
127. Paczesny S., Banchereau J., Wittkowski K.M., Saracino G., Fay J., and Palucka A.K. Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitor-derived dendritic cells. J Exp Med 199 (2004) 1503-1511
128. Sallusto F., and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179 (1994) 1109-1118
129. Morse M.A., Lyerly H.K., and Li Y. The role of IL-13 in the generation of dendritic cells in vitro. J Immunother 22 (1999) 506-513
130. de Vries I.J., Lesterhuis W.J., Scharenborg N.M., Engelen L.P., Ruiter D.J., Gerritsen, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9 (2003) 5091-5100
131. McIlroy D., and Gregoire M. Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 52 (2003) 583-591
132. Jonuleit H., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27 (1997) 3135-3142
133. Schadendorf D., Ugurel S., Schuler-Thurner B., Nestle F.O., Enk A., Brocker E.B., et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17 (2006) 563-570
134. Parlato S., Santini S.M., Lapenta C., Di Pucchio T., Logozzi M., Spada M., et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98 (2001) 3022-3029
135. + T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother. 55 (2006) 469-474
136. Czerniecki B.J., Koski G.K., Koldovsky U., Xu S., Cohen P.A., Mick R., et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67 (2007) 1842-1852
137. Gilboa E. DC-based cancer vaccines. J Clin Invest 117 (2007) 1195-1203
138. http://www.mmri.mater.org.au.
139. Dillmann O.R., Selvan S.R., and Schiltz P.M. Patient-specific dendritic-cell vaccines for metastatic melanoma. N Engl J Med 355 (2006) 1179-1181
140. Lu W., Arraes L.C., Ferreira W.T., and Andrieu J.M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 10 (2004) 1359-1365
141. Scandella E., Men Y., Gillessen S., Forster R., and Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100 (2002) 1354-1361
142. Luft T., Jefford M., Luetjens P., Toy T., Hochrein H., Masterman K.A., et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 100 (2002) 1362-1372
143. Morelli A.E., and Thomson A.W. Dendritic cells under the spell of prostaglandins. Trends Immunol 24 (2003) 108-111
144. + T cell populations lacking helper function. Nat Immunol 6 (2005) 163-170
145. Banerjee D.K., Dhodapkar M.V., Matayeva E., Steinman R.M., and Dhodapkar K.M. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108 (2006) 2655-2661